Prevalence of Terminal Renal Disease in Lupus Nephritis Patients
2017 UBT International Conference, Page: 43-47
2017
- 154Usage
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Usage154
- Downloads127
- Abstract Views27
Conference Paper Description
Systemic erythematosus lupus is a chronic inflammatory disease of autoimmune nature. This illness can affect all organs, but one of the most common illnesses is lupus nephritis. Patients with renal impairment, despite aggressive immunosuppressive medication carry the risk of developing terminal renal disease and doing dialysis or renal transplant.The purpose of this study is to reflect global statistics on the frequency of the development of terminal renal disease in lupus nephritis patients as an awareness-raising way to stimulate studies that present a successful treatment or screening protocol in preventing this complication.This study is a review based on the research of world studies and literature regarding the prevalence of terminal renal disease in lupus nephritis patients.Over 50% of patients with LES, depending on different regions of the world, race / ethnicity develop lupus nephritis. 10-30% of lupus nephritis cases develop terminal renal disease where among the major risk factors are new age, nephrotic proteinuria, disease activity index, histological class of renal impairment, high creatinine, lack of remission, etc. Performing as early as possible the renal transplant increases the lifespan of patients with terminal renal disease.It is very difficult to prevent renal impairment in patients with LES, more so when some of them have lupus nephritis as the initial manifestation. However, since more than 50% of LES patients develop lupus nephritis and 10 to 30% of lupus nephritis cases develop terminal renal disease, studies should be encouraged to determine a successful treatment or screening protocol in preventing this complication.
Bibliographic Details
https://knowledgecenter.ubt-uni.net/conference/2017/all-events/289; http://dx.doi.org/10.33107/ubt-ic.2017.289; https://knowledgecenter.ubt-uni.net/cgi/viewcontent.cgi?article=1431&context=conference; https://dx.doi.org/10.33107/ubt-ic.2017.289; https://knowledgecenter.ubt-uni.net/conference/2017/all-events/289/
University for Business and Technology
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know